🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. VP-102 - Cantharidin, Topical Film Forming Solution

    Verrica Pharmaceuticals

    Molluscum Contagiosum

    phase 3 other completed

    2 trials

  2. VX-880 solution for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia

    phase 3 small molecule active

    1 trial

  3. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Chronic migraine

    phase 3 small molecule active

    1 trial

  4. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule active

    1 trial

  5. VYEPTI 100 mg concentrate for solution for infusion, Nacl 0.9%

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule active

    1 trial

  6. Vectibix 20 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    Unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  7. Venclexta, Venclyxto, Levact 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Venclexta, Venclyxto, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Venclexta, Venclyxto, Fludarabin Ebewe 25 mg/ml injektio-/infuusiokonsentraatti, liuosta varten, Fludarabin Sandoz 25 mg/ml injekčný alebo infúzny koncentrát, MabThera 500 mg concentrate for solution for infusion, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, Bendamustin cell pharm® 2,5

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  8. Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, BGB-11417, MabThera 100 mg concentrate for solution for infusion, BGB-11417, BGB-11417, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, MabThera 500 mg concentrate for solution for infusion, Venclyxto 50 mg film-coated tablets

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  9. Venclyxto 100 mg film-coated tablets, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, BGB-16673, BGB-16673, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Zydelig 150 mg film-coated tablets, Zydelig 100 mg film-coated tablets

    BEONE MEDICINES AUS PTY LTD

    Chronic lymphotic leukemia and Small Lymphocytic lymphoma

    phase 3 small molecule active

    1 trial

  10. Venclyxto 100 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, Zanubrutinib, Venclyxto 50 mg film-coated tablets

    BEONE MEDICINES AUS PTY LTD

    Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  11. Venetoclax, Venetoclax, Cytarabine 100 mg/ml Solution for Injection or Infusion, Matching Placebo for Venetoclax, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  12. Venetoclax, Venetoclax, Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg film-coated tablets, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  13. Venofer 20 mg iron / ml, solution for injection or concentrate for solution for infusion., Ferumoxytol

    Lacuna Pharma Pty Ltd

    Iron Deficiency Anemia (IDA)

    phase 3 small molecule active

    1 trial

  14. Venofer 20 mg iron / ml, solution for injection or concentrate for solution for infusion., Ferumoxytol

    Lacuna Pharma Pty Ltd

    Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease (CKD)

    phase 3 small molecule active

    1 trial

  15. Verzenios 150 mg film-coated tablets, Kisqali 200 mg film-coated tablets, Faslodex 250 mg solution for injection., IBRANCE 75 mg film-coated tablets, LEUPRORELIN , Verzenios 100 mg film-coated tablets, RO7197597, RIBOCICLIB, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, Verzenios 50 mg film-coated tablets

    Hoffmann-La Roche

    Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  16. Vincristine placebo, VINCRISTINE , Polivy 140 mg powder for concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Previously Untreated Diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  17. Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 3 small molecule active

    1 trial

  18. Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    1 trial

  19. Voxzogo 1.2 mg powder and solvent for solution for injection, powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 3 small molecule active

    1 trial

  20. Vyloy 100 mg powder for concentrate for solution for infusion., OXALIPLATIN, FOLINIC ACID, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, FLUOROURACIL, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Vyloy 100 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sodium chloride 0.9% intravenous infusion, ASP8951, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate fo

    Astellas Pharma GmbH

    Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  21. Vyvgart 1 000 mg solution for injection

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  22. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo PH20 SC

    argenx

    Ocular Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  23. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo for efgartigimod

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  24. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis (gMG)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources